RAD51 and breast cancer: Overall in silico revealed similar RAD51 expression trends to those observed with cell lines and patient immunohistochemistry, consistent with the notion that RAD51 expression is increased during breast cancer progression and metastasis, suggesting an oncogenic role when deregulated.